Does Oral BPC-157 Work? Nobody Has Measured It in People

Nobody knows whether swallowed BPC-157 reaches the bloodstream, because no published study has measured it in a human being. FDA went looking in May 2026 and reported the result plainly: "We found no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal administration."¹

That sentence covers four of the five routes BPC-157 is sold in, and it is quoted here instead of paraphrased because the agency deciding whether pharmacies could compound the stuff wrote it. Capsules, subcutaneous injections, nasal sprays and creams all sit on the same empty shelf. Nobody can say which delivery method works better than another, because neither side of the comparison has been measured.

Does oral BPC-157 get absorbed?

Oral absorption of BPC-157 has never been measured in a person, so nobody can say. Capsules at 250 micrograms, 500 micrograms and 1 milligram were among the products proposed to FDA for compounding.¹ No human pharmacokinetic study of any of them exists in the published literature that FDA could find.

Sellers often present oral BPC-157 as the convenient version of the injection, implying the two deliver comparable amounts of peptide. That claim needs a number on both sides to mean anything, and there is no number on either side.

FDA's document is not quite consistent about the capsule itself. Its introduction lists the proposed strengths as "Capsule: 250 μg, 500 μg, and 1 mg, oral," while the characterization section refers to "the proposed capsule (25 µg, 500 µg, and 1 mg)."¹ A ladder of 250, 500 and 1,000 micrograms makes sense and 25 does not, so the second mention looks like the error, but the document prints both.

Our guide to whether peptide capsules, nasal sprays and creams work covers the general problem across compounds, and BPC-157 is the sharpest case of it. A peptide with a large retail market and no absorption data at all is unusual even in this field.

What was FDA looking for?

FDA was looking for pharmacokinetic studies, the kind that track how much of a dose reaches the blood and how long it stays. Its evaluation covered both the free base and the acetate salt, and it searched the published literature, adverse event databases and the clinical trials registry.¹

What it found for humans was one route and two studies. Everything else came back empty, and the agency recorded that emptiness route by route instead of in general terms. The phrase it uses for the five proposed routes recurs throughout the document as "the nominated ROAs (oral, rectal, transdermal, SC, and nasal)," where ROA is route of administration.¹

One distinction carries real weight here. An absence of data is not a finding that something fails. FDA did not conclude that oral BPC-157 is unabsorbed. It concluded that nobody has checked, a different and in some ways more awkward position.

Why is swallowing a peptide hard?

Peptides are hard to swallow usefully because the digestive tract exists to take them apart. Protein in food is broken into fragments by stomach acid and then by enzymes in the small intestine, and a therapeutic peptide arriving by the same door meets the same machinery. Anything surviving that still has to cross the gut wall to reach the blood, the second of two barriers and the one nobody has tested here.

FDA's evaluation measures neither step for BPC-157, but it does flag which routes depend on the solid dissolving inside you. Particle size was missing from the nomination packages, and the agency notes the gap may bear on "process/product performance of the proposed capsule" along with the suppository and the transdermal cream.¹ For the injection and the nasal spray it reaches the opposite conclusion, because the powder dissolves in water at 5 milligrams per millilitre and would be put into solution before anyone received it, so particle size is not treated as a critical quality attribute for those two.¹

Read that split across the route list and it falls out cleanly. Capsule, suppository and cream all arrive as a solid and rely on the body to dissolve them. Injection and nasal spray arrive already dissolved, so the body is not asked to do that part. BPC-157 is a fifteen amino acid chain with a molecular weight FDA gives as 1419.5 grams per mole, large for a molecule expected to cross a membrane unaided, and the three routes where the solid form matters are three of the four a pharmacy may now compound.¹

Does BPC-157 survive stomach acid?

Survival in stomach acid is the one part of this where BPC-157 has a real argument in its favor, and it deserves stating properly. The peptide was originally isolated from human gastric juice, and FDA notes that it "was reported to be resistant to hydrolysis in gastric juice in vitro."¹

A peptide that holds together in stomach acid in a test tube is a more plausible oral candidate than most. Anyone defending oral BPC-157 should lead with that finding, because it is genuine and it comes from the regulator's own document rather than from marketing.

What it does not establish is absorption. Surviving the stomach gets a molecule as far as the gut wall, and FDA attributes the peptide's short half-life in animals, 5.3 minutes in dogs and 15.2 minutes in rats, to breakdown by enzymes in blood and tissue instead.¹ Something that clears that fast has to get in before it can do anything, and getting in is the step nobody has measured.

What happened to the one oral trial?

One registered trial set out to answer exactly this question and then went quiet. FDA found a single phase 1 study in healthy subjects in Mexico, registered as NCT02637284, in which participants were to receive BPC-157 as an oral tablet, first as a single dose and then every eight hours for two weeks, with an estimated enrollment of 42.¹

The agency's note on it is one sentence: "There are no results posted, and we were unable to find an associated published study."¹

Registered trials go unpublished for many reasons, including funding, recruitment and commercial decisions, so this is not evidence that something went wrong. It is evidence that the obvious study was attempted and its results are not available to anyone, and the question is still open a decade later.

Does injected BPC-157 have human data?

Injected BPC-157 has no human pharmacokinetic data either, a fact that surprises people who assume the needle route is the established one. Subcutaneous injection at 2,000 micrograms per millilitre was the second product proposed to FDA, and it sits in the same sentence as the capsule in the agency's finding of no human data.¹

Animal injection studies do exist and some are reasonably thorough. In Sprague Dawley rats and Beagle dogs dosed intramuscularly, both the area under the curve and the peak plasma concentration rose in proportion to the dose, and FDA reads that as evidence of first-order kinetics.¹ Repeat-dose toxicity studies ran 28 days in both species.¹

None of that tells you what happens in a person. Injecting a peptide under the skin of a human and measuring what arrives in the blood is an ordinary study design, and it has not been published for this compound.

Which route has any human data at all?

Rectal administration is the only route with human data, and the data are not what most readers would expect. Two studies gave BPC-157 as an enema, one to healthy volunteers and one to people with ulcerative colitis, and FDA's exposure table lists them as "Up to 2 mg/kg rectal enema once daily x 8 days (n=24 healthy subjects)" and "80 mg rectal enema once daily x 2 weeks (approximately 26 subjects with UC)."¹

Those figures are reproduced here as the regulator printed them, not as doses for anyone to copy. Total human exposure on record runs to roughly fifty people for a maximum of two weeks, and FDA records that no serious adverse events were reported in either study.¹

A suppository at 1 milligram was among the nominated products. Sensible enough for a gut condition, and no use whatever for a tendon.¹ The gap between what was studied and what people buy BPC-157 for is almost total.

What does "not detected in plasma" mean?

Not detected means the assay looked for BPC-157 in the participants' blood and did not find it. FDA reports that "In both studies, authors report that BPC-157 was not detected in plasma samples," and that in one abstract the authors state that "most" concentrations fell below the lower limit of quantification of the method used.¹

The agency's own reading of that result is the single most useful line in the document for anyone weighing routes: "There is no information to assess the pharmacokinetics of BPC-157 in humans; however, it does not appear that BPC-157 is absorbed systemically when given as a rectal enema."¹

Two readings are available and they point in opposite directions. Either the peptide acts locally on gut tissue without needing to enter the bloodstream, a reasonable mechanism for a colitis treatment, or very little of it got anywhere. Both are consistent with the data, and neither has anything to say about a capsule or an injection.

Which routes were nominated, and which are permitted?

Five routes were nominated and four are permitted, and the two lists do not match. FDA lists the proposed products as "Capsule: 250 μg, 500 μg, and 1 mg, oral," "Injection: 2,000 μg/mL, subcutaneous (SC)," "Nasal spray solution: 50 μg/spray (500 μg/mL), nasal," "Suppository: 1 mg, rectal," and "Transdermal cream."¹ The October 2026 policy limits BPC-157 to "subcutaneous, intramuscular, oral, and topical dosage forms."²

Read down the human data column and the comparison people want, pills against injections, collapses. Both are blank. The only row with anything in it is the row that is no longer allowed.

Why is intramuscular on the permitted list?

Intramuscular was never nominated, and no document available explains how it arrived. It appears more than twenty times in FDA's evaluation and every appearance is an animal study in rats, dogs or mice.¹

Using intramuscular dosing in animals is normal practice, because it gives clean and reproducible exposure for toxicology work. The route was a laboratory choice, not a proposal for how people would take the compound.

Appendix B is not a blanket permission for injections either, because it treats each of the six peptides differently. TB-500 and MOTS-c are limited to injectable forms, KPV to topical and oral, and Semax to intranasal use.² BPC-157 has the widest permitted set of the six, and it is the only one of them that picked up a route its nomination never mentioned.

So one of the four routes a pharmacy may now compound entered the record only because it was how the animals were dosed. For a reader comparing delivery methods, nothing else about the permitted list matters as much: it is not a ranking of what works.

Can the animal injection data fill the gap?

No, and FDA says why in terms that apply directly to the pills versus injection question. Translating a safe dose from one route to another requires knowing what fraction of each dose reaches the bloodstream, and that figure does not exist for BPC-157 by any route.

FDA puts it this way: "since studies were not identified to establish the absolute bioavailability of BPC-157 delivered via IM and the nominated ROAs to rats and dogs, it is not possible to use the IM NOAELs to estimate the NOAELs for the nominated ROAs."¹ A NOAEL is the highest dose at which no harmful effect was observed.

FDA also records that it "did not identify nonclinical pharmacokinetic and toxicological studies of BPC-157 (free base) or BPC-157 acetate delivered via the nominated ROAs (oral, rectal, transdermal, SC, and nasal)."¹ Animal and human records have the same hole in the same place, so there is no bridge from one route to another in either species.

What does the oral bioavailability condition require?

The policy attaches a requirement to oral BPC-157 that no other route carries. It sits in the list as condition 8. Under condition 8 a compounder must document that its particular formulation achieves adequate oral bioavailability in humans.²

Taken on its own that is careful drafting. Somebody evidently recognized that swallowing a peptide is the hardest case of the five and decided a pharmacy should have to show its own product gets absorbed before selling it.

No equivalent condition attaches to the subcutaneous injection, the intramuscular injection or the cream. The policy's other requirements cover where the raw peptide comes from, what testing it gets, what the label must say and what a pharmacy must report, and none of those ask for evidence that the product reaches the bloodstream.²

Nobody asks for proof of absorption on a route they consider settled, and a requirement that lands on the capsule and not on the injection says plainly enough which of the two the drafters thought was shakiest.

Can anyone meet that condition today?

Whether the condition can currently be met depends on data FDA could not find five months before the policy was written. Its search returned "no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal administration," and condition 8 asks a compounder for human bioavailability documentation on its specific oral formulation.¹²

Two possibilities exist and the documents do not settle between them. Unpublished formulation-level human data may exist somewhere, plausible enough for proprietary work, or the condition cannot be satisfied by anyone right now and the oral route is open in principle and closed in practice.

Nobody should treat the second possibility as a scandal. A conditional permission that nobody can yet satisfy is a sensible way to leave room for future evidence. It does mean that a bottle of oral BPC-157 capsules on sale today is not evidence that anyone demonstrated absorption.

Did FDA think the evidence was enough?

FDA did not think the evidence was enough, and it said so before the policy existed. Its evaluation closes: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List."¹ All four of the criteria it applies came out against the substance, including a finding of "insufficient clinical safety information to characterize the safety profile of" the two forms.¹

The advisory committee heard that argument on July 23, 2026 and voted the other way, 8 to 6 with one abstention, after which HHS produced the route table.³ One qualification belongs on this: FDA states on the cover of each briefing document that it will not issue a final determination until the committee process is complete, so the evaluation is its proposal going in, not a verdict.¹

Our coverage of what HHS actually allowed walks through the conditions a pharmacy has to meet. The point for route comparison is narrower. The permitted list was not built from evidence about which route delivers the peptide, because no such evidence was before anyone.

What would settle this?

One study would settle most of it. Give BPC-157 to healthy volunteers by mouth and by subcutaneous injection, draw blood over the following hours, and report the concentrations. That is an ordinary phase 1 design, and it has been registered once already as NCT02637284, with no results posted and no published study FDA could locate.¹

Absorption is not the only gap FDA recorded, either. Particle size data was absent for the three solid-form routes, and for the nasal spray the agency noted that container, closure and pump are critical components while there was "a lack of information about what type of device" would be used, "nor any information for a control strategy to assure the product CQAs which are critical for the safety and effectiveness of the compounded product."¹ That is a plausible reason the nasal route did not survive into the permitted list, and it is a device problem instead of an absorption one.

Until the absorption study exists, anyone choosing between a capsule and a syringe is choosing on grounds other than measured absorption. Our guide to whether BPC-157 works at all covers the clinical evidence question, and the oral salt forms guide covers the arginate and acetate distinction that sellers rarely state.

The route you cannot currently buy is the only one anyone has measured, and in that one the peptide did not show up in blood.

Common questions

Does oral BPC-157 work?

Is oral or injected BPC-157 better?

Does BPC-157 survive stomach acid?

Has anyone studied oral BPC-157 in humans?

Which BPC-157 route has human data?

Was BPC-157 found in the blood in those studies?

Does that mean BPC-157 does not get absorbed?

Why is BPC-157 hard to absorb by mouth?

Which BPC-157 routes can a pharmacy compound?

Why is intramuscular permitted if it was not nominated?

Can animal data show oral BPC-157 is safe?

What does the oral bioavailability condition mean for buyers?

Did FDA support adding BPC-157 to the compounding list?

Is a nasal BPC-157 spray allowed?

How much human exposure data exists in total?

What study would answer the oral question?

Sources

1. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23 to 24, 2026. BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Evaluation memorandum dated 5/11/2026. Read at source from the full PDF, with the text extracted from the document's own text layer and every quotation on this page checked character for character against it. No other source on this page is verified that way. Quoted for the absence of human pharmacokinetic data by four routes, the nominated product list and strengths, the human exposure table, the rectal plasma findings, the gastric juice resistance report, the molecular weight, the animal half-life figures, the intramuscular animal toxicology, the NOAEL extrapolation limit, the registered oral trial with no posted results, the safety criterion conclusion and the final recommendation. Source document. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40 ↩41 ↩42 ↩43 ↩44 ↩45 ↩46 ↩47 ↩48 ↩49 ↩50 ↩51
2. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B and conditions 1 through 10. Federal Register document number 2026-22192, docket HHS-OASH-2026-0496, published October 30, 2026. Not independently retrieved for this page. federalregister.gov declines automated retrieval, so the Appendix B dosage form limits and the oral bioavailability condition are reported here as stated on this site's own earlier coverage of the policy. That page read the Federal Register public inspection PDF at source. Treat the Appendix B wording as second-hand until the PDF is checked directly. Source document. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
3. The American Journal of Managed Care. Report on the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting, published July 31, 2026. Read via automated page retrieval. Quoted only for the BPC-157 vote tally. This is trade press reporting a meeting outcome rather than a primary record, and the figure should be replaced with the committee's own minutes when FDA posts them. Source document. ↩1 ↩2